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1. Introduction 
Generalized anxiety, panic, and posttraumatic stress disorder (PTSD) are debilitating 
conditions, which have an incidence of one in ten persons in the general population and 
epidemiological studies also report that these disorders often occur with depression (1-3). 
Anxiolytic benzodiazepines, including diazepam and alprazolam, remain the best and most 
used treatments for these conditions (4-7). However, their therapeutic use is associated with 
side effects, which include sedation and rapid development of tolerance as well as 
dependence. This results in severe discontinuation symptoms and often to drug abuse (4-6, 
8; 9).  
In many patients, including patients with PTSD, the pharmacological effects of these drugs 
are very weak and there is a large number of non-responders (10-12). This has stimulated 
drug design that for many decades has focused in the development of new more effective 
therapies for anxiety disorders (13-15). Novel neuronal biomarkers for the pharmacological 
targets of the next generation of anxiolytic drugs have been discovered. 
The downregulation of neurosteroid biosynthesis has been implicated in the 
pathophysiology of anxiety and depressive disorders (reviewed in 16). Decreases in 
cerebrospinal fluid (clinical studies) and brain content (preclinical studies) of the GABAA 
receptor-active progesterone derivative, allopregnanolone, have been associated with 
affective and mood disorders, which includes depression, anxiety spectrum disorders, 
PTSD, premenstrual dysphoric disorder, schizophrenia, and impulsivity (17-27). Thus, 
elevating or normalizing the downregulation of brain allopregnanolone levels could be a 
promising therapeutic strategy for these psychiatric disorders. This prompted investigations 
to develop new neurosteroidogenic agents to contrast allopregnanolone biosynthesis deficits 
in anxiety and depression (28-31). 
We measured allopregnanolone levels in the cerebrospinal fluid (CSF) of PTSD patients 
assuming that allopregnanolone levels in the CSF reflect the levels of this neurosteroid in the 
brain (17). Also, in depressed patients, the concentration of allopregnanolone in the CSF was 
decreased by about 50-60% of the levels measured in non-psychiatric patients (26). The CSF 
allopregnanolone level decrease is likely induced by a downregulation of the expression of 
5┙-reductase type I mRNA in the prefrontal-cortex (area BA9) that we measured in 
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depressed patients and age- and sex-matched non-psychiatric subjects (32). The cortical level 
of 5┙-reductase mRNA in depressed patients was dramatically decreased to about 50% of 
the levels measured in non-psychiatric comparison subjects, whereas the levels of 5┙-
reductase mRNA was unchanged in the cerebellum (32). In depressed patients, SSRI 
treatment with fluoxetine and fluvoxamine normalized the CSF allopregnanolone content 
(26) in a manner that correlated with the improvement in depressive symptoms. These 
results were confirmed in studies that determined allopregnanolone or levels of 5┙-
tetrahydrodeoxycorticosterone, another positive modulator of GABAA receptor function, in 
the plasma of depressed patients treated with SSRIs (33).  
In premenopausal women with PTSD, the CSF allopregnanolone levels were decreased by 
about 60% and were inversely correlated with PTSD re-experiencing and comorbid depressive 
symptoms (17). Interestingly, CSF allopregnanolone levels were lowest in those patients with 
PTSD and comorbid depression. Also, the ratio of allopregnanolone to its steroid precursor, 5┙-
dihydroprogesterone (5-DHP), was decreased among the PTSD patients, suggesting the 
presence of an impairment in the biosynthesis of allopregnanolone from its precursor 5-DHP 
(17). These data suggest that the downregulation of brain allopregnanolone levels in PTSD and 
depressed patients may cause a GABAergic neurotransmission dysfunction, which in turn 
results in the behavioral symptoms seen in these patients. 
Following the finding that fluoxetine and paroxetine and other SSRIs increase the content of 
allopregnanolone in several rodent brain structures (34), we hypothesized that normalization 
of brain allopregnanolone levels may underlie the pharmacological effects of the so called 
“selective serotonin reuptake inhibitors” or SSRIs in mood disorders. To test this hypothesis, 
we conducted experiments using the socially isolated mouse as an animal model of anxiety 
disorders and PTSD (16; 35-38). The socially isolated mouse expresses a robust decrease of 
corticolimbic allopregnanolone levels, which are associated with anxiety-like behaviors, fear, 
resistance to sedation, and heightened aggression (16; 35; 39). These behavioral deficits can be 
ameliorated by administration of fluoxetine and other SSRIs that upregulate allopregnanolone 
levels. Interestingly, fluoxetine’s pharmacological effects resulted to be independent from the 
ability of this drug to inhibit serotonin reuptake (35; 36). 
Our experiments support a selective and novel mechanism whereby SSRIs, acting as selective 
brain steroidogenic stimulants (SBSSs), increase brain corticolimbic allopregnanolone levels and 
improve PTSD, anxiety, and depression behavioral symptoms. 
2. Neurosteroids modulation of GABAA receptors function 
Biosynthesis of neurosteroids in the brain is independent from adrenals, ovaries, and testis 
(40-44). Neurosteroids are functionally active in modulating gene expression and 
neurotransmitter systems (45-52). Allopregnanolone exerts pharmacological actions, such as 
anticonvulsant, anxiolytic, antidepressant, and even sedative-hypnotic (53-60). These 
pharmacological actions are similar to those elicited by barbiturates and benzodiazepines 
(52; 61; 62). Allopregnanolone potently (nM affinity), positively, and allosterically modulates 
the action of GABA at GABAA receptors (45-51). The endogenous physiological relevance of 
allopregnanolone is substantiated by its facilitation and fine-tuning of the efficacy of direct 
GABAA receptor activators and positive allosteric modulators of GABA action at GABAA 
receptors (43; 47; 48; 63). The demonstration that allopregnanolone potentiates GABA 
responses via two binding sites in the GABAA receptor that, respectively, mediate the 
potentiation and the direct activation of the GABAA receptor by allopregnanolone has been 
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pivotal in neurosteroid pharmacology (64). Also, GABAA receptors incorporating ┙4, ┙6, 
and ├ subunits in combination with ┛ and ┚ subunits show higher affinity (nM range) for 
allopregnanolone (45; 46; 51; 64; 65). Relevant for pharmacological strategies to overcome 
behavioral deficits resulting from GABAA receptor signal transduction deficits, 
allopregnanolone allosteric modulation of the action of GABA at GABAA receptors is much 
less selective than that of benzodiazepines, which are relatively inactive at ┙4- or ┙6-
containing GABAA receptors (4; 45; 46; 66). 
3. Neurosteroid biosynthesis in corticolimbic neurons  
A study of the neuronal localization of the neurosteroidogenic enzymes, 5┙-reductase type I 
and 3┙-hydroxysteroid dehydrogenase (3-HSD), has recently showed that these enzymes 
are not expressed in GABAergic cortical interneurons or glial cells (67). Of note, 5┙-
reductase and 3┙-HSD were highly expressed and co-localized in a region-specific way in 
primary GABAergic and glutamatergic neurons, including pyramidal neurons, granular 
cells, reticulo-thalamic neurons, medium spiny neurons of the striatum and nucleus 
accumbens, and Purkinje cells in the cerebellum (67). This suggested that allopregnanolone 
synthesized in glutamatergic cortical or hippocampal pyramidal neurons or in granular cells 
of the dentate gyrus may be secreted in: 1) a paracrine manner which would allow 
allopregnanolone to reach GABAA receptors located in the synaptic membranes of other 
cortical or hippocampal pyramidal neurons, or 2) an autocrine fashion which would allow 
allopregnanolone to act locally by binding post-synaptic or extra-synaptic GABAA receptors 
located on the same dendrites or cell bodies of the cortical or hippocampal pyramidal 
neuron in which it was produced (67). Alternatively, allopregnanolone might not be 
released, but may instead diffuse laterally into synaptosome membranes of the cell bodies or 
dendritic arborization of glutamatergic neurons in which it is produced to attain 
intracellular access to specific neurosteroid binding sites of GABAA receptors (67; 68). In the 
amygdala, for example, this would functionally baffle the effects of concomitant excitatory 
inputs to glutamatergic projection neurons during exposure to unconditioned stress during 
fear conditioning or to conditioned stressors during extinction.  
On the other hand, allopregnanolone produced in primary output GABAergic neurons from 
the reticular thalamic nucleus may secrete allopregnanolone simultaneously with GABA to 
concomitantly act at post-synaptic GABAA receptors inserted in glutamatergic thalamocortical 
neurons (69). Very similarly, allopregnanolone synthesized by striatal medium spiny 
GABAergic neurons and cerebellar Purkinje cells may activate post-synaptic GABAA receptors 
located on cell bodies or dendrites of neurons in the deep cerebellar nuclei (67). 
The clarification of allopregnanolone site of synthesis and action across several brain regions 
has been pivotal to our understanding of the possible mechanisms by which 
allopregnanolone is secreted and acts at GABAA receptors. These studies underscore the 
functional role of allopregnanolone in fine tuning the strength of GABAergic 
neurotransmission under physiological conditions and how deficits in allopregnanolone 
biosynthesis may result in abnormal behavior.  
4. Social isolation induces a selective neuron-specific decrease of 5-
reductase in corticolimbic neurons 
Exposure of rodents to protracted social isolation stress for 4-8 weeks induces a decrease in 
allopregnanolone biosynthesis in several corticolimbic structures as a result of a 
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downregulation of the mRNA and protein expression of 5-reductase type I (35; 70-73; 
reviewed in 38). Socially isolated mice show a 70% reduction in the synthesis rate of 
allopregnanolone and 5-DHP biosynthesis compared to group-housed mice (35; 72). 
Allopregnanolone and 5┙-DHP are unevenly distributed and expressed in various brain 
structures (48; 74). The rodent olfactory bulb shows the highest concentrations of 5┙-DHP and 
allopregnanolone followed by the frontal cortex, hippocampus, amygdala, striatum, and 
cerebellum (74). Interestingly, the largest decrease of 5-reductase was found in brain regions 
regulating emotional behavior, including the amygdala and hippocampus, followed by the 
olfactory bulb and the frontal cortex (74). The expression of 5-reductase failed to change in 
the cerebellum and striatum (74; 75). Decreased 5-reductase was specifically found in cortical 
pyramidal neurons of layers V-VI, in hippocampal CA3 pyramidal neurons and glutamatergic 
granular cells of the dentate gyrus, and in the pyramidal-like neurons of the basolateral 
amygdala (75). However, 5-reductase fails to change in GABAergic neurons of the reticular 
thalamic nucleus, central amygdala, cerebellum, and in the medium spiny neurons of the 
caudatus and putamen (75). In these brain areas, we confirmed that the decrease of 5-
reductase resulted in a reduction of allopregnanolone levels (74; 76; 77).  Social isolation failed 
to change the expression of 3-HSD, the mRNA expression of diazepam binding inhibitor, and 
the expression of the 18 kDa translocase protein (TSPO), which is involved in the transport of 
cholesterol across the inner mitochondrial membrane and activation of neurosteroidogenesis 
(reviewed in 72). Thus, the downregulation of 5-reductase appears to be the main factor 
responsible for the reduction of corticolimbic allopregnanolone levels. 
5. GABAergic neurotransmission deficits resulting from allopregnanolone 
downregulation 
Allopregnanolone biosynthesis downregulation as a result of social isolation stress or 
pharmacological decrease of allopregnanolone induced by inhibiting 5-reductase with the 
potent competitive 5-reductase inhibitor SKF 105,111 decreases GABAergic 
neurotransmission as demonstrated by reduced loss of righting reflexes induced by GABAA 
receptor active ligands. The effects of SKF on the muscimol-, pentobarbital-, 
benzodiazepine-, or alcohol-induced loss of righting reflex loss can be reversed by the 
systemic or intracerebroventricular administration of allopregnanolone (43; 48). Likewise, 
social isolation or SKF-induced decrease of allopregnanolone results in facilitation of the 
seizure activity induced by several drugs that decrease GABAA receptor function, including 
picrotoxin (63). Administration of allopregnanolone at doses that have virtually no effects 
on group-housed control mice normalized the increased susceptibility to picrotoxin-induced 
seizures in SKF-treated or social isolated mice (63). The protracted social isolation or SKF 
treatment-induced allopregnanolone biosynthesis downregulation appeared to be the 
primary reason for the GABAA receptor signal transduction deficits observed in these mice. 
In fact, seizures induced by kainic acid or strychnine in socially isolated mice are similar to 
those induced by these agents in group housed mice.     
6. Behavioral effects induced by allopregnanolone downregulation in 
corticolimbic areas 
The decrease of allopregnanolone biosynthesis in socially isolated mice has been associated 
with several behavioral deficits that resemble behavioral abnormalities observed in patients 
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with PTSD (16; 17; 30; 38). Hence, this mouse model can be used to study the behavioral 
responses elicited by treatment with neurosteroidogenic agents, the SBSSs. This new class of 
drugs includes the SSRI antidepressants that have been shown to elicit a potent 
neurosteroidogenic activity selectively at low doses as their principal action.  
Allopregnanolone has emerged as an important biomarker of emotional behavioral deficits 
(16; 35-38; 72). This was demonstrated by experiments using socially isolated mice to induce 
a downregulation of allopregnanolone biosynthesis. We have established a fundamental 
role for allopregnanolone in the regulation of anxiety-like and aggressive behavior as well as 
contextual fear conditioning, (16; 37; 63; 74; 77). When mice are socially isolated for a period 
varying from one to eight weeks, there is a time-dependent increase in aggressive behavior 
over the first four weeks of isolation, which is inversely correlated with a time-dependent 
decrease of corticolimbic allopregnanolone levels (35). Likewise, socially isolated mice 
exposed to a classical fear conditioning paradigm showed enhanced conditioned contextual 
but not cued fear responses compared with group housed mice (74). The time-related 
increase of contextual fear responses correlated with the downregulation of 5-reductase 
mRNA and protein expression observed in the frontal cortex, hippocampus, and amygdala 
(74). Socially isolated mice also exhibited impaired and incomplete fear extinction (74). Of 
note, socially isolated mice also exhibit higher levels of anxiety-like behavior, determined by 
the elevated plus maze and in the open field (16; 39).    
Allopregnanolone plays a pivotal rather than incidental role in the regulation of contextual 
fear responses and aggression. In fact, pharmacological treatment with allopregnanolone 
dose-dependently decreased aggression in a manner that correlated with an increase in 
corticolimbic allopregnanolone content (35). Allopregnanolone also normalized the 
exaggerated contextual fear responses and anxiety of socially isolated mice (74). Further, 
administration of the potent 5┙-reductase competitive inhibitor SKF 105,111 to normal 
group-housed mice (43; 48; 47) rapidly (~1 h) decreased levels of allopregnanolone in the 
olfactory bulb, frontal cortex, hippocampus, and amygdala by 80-90% (73; 74) in association 
with a dose-dependent increase of conditioned contextual fear responses (74). 
Administering allopregnanolone doses that normalized hippocampus allopregnanolone 
levels reversed the effects of SKF 105,111 on conditioned contextual fear responses (74). 
These results are in agreement with results of many other investigators who have observed 
that allopregnanolone elicits anxiolytic and antidepressant effects (39; 54; 78-84). 
7. Social isolation induces changes in GABAA receptor subunit expression 
Postmortem studies suggest that altered corticolimbic GABAergic neurotransmission, 
GABA receptor binding and receptor subunit composition, as well as GABA synthesis and 
transport may be associated with various psychiatric disorders, including anxiety disorders, 
schizophrenia, and depression (85-88). 
The regional distribution of GABAA receptor subunit subtypes plays an important role in the 
pharmacology of GABAA receptor ligands that bind to selective and specific GABAA receptor 
subunits (89-90). Recent studies showed that -containing GABAA receptors mediate the 
sedative properties of specific GABAergic ligands, such as diazepam, in the same way  and 
probably subunits mediate the anxiolytic effects of benzodiazepines, and subunits 
appear to be involved in learning and cognition (89; 90). High affinity binding of 
benzodiazepine to GABAA receptors requires the interaction of and  subunits (89; 90). 
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In socially isolated mice, we found changes in the mRNA and protein expression of several 
GABAA receptor subunits in the frontal cortex and hippocampus (91). The mRNA levels 
encoding , and  GABAA receptor subunit subtypes were reduced (~50%), while the 
mRNAs encoding  and subunits were increased (~130%) compared to levels measured 
in group-housed mice (91). Protein levels of and  determined in synaptic membrane 
preparations in the frontal cortex and hippocampus confirmed the former results. Using a 
laser microdissection technique coupled with nested RT-PCR amplification, we found that 
 mRNA levels were decreased by 50% in layer I neuropil, whereas the expression of 
subunit mRNA in the pyramidal neurons of layer V was unchanged as a result of social 
isolation. Thus, changes in GABAA receptor subunits within one brain area are region-
specific (91). 
Changes in GABAA receptor subunit subtype composition are expected to result in altered 
pharmacological responses to various GABAA receptor ligands in socially isolated mice. As 
expected, socially isolated mice showed resistance to the sedative and anxiolytic properties of 
diazepam and zolpidem, positive allosteric GABAA receptor modulators that bind with high 
affinity to  or subunit-containing GABAA receptors (diazepam) and to  subunit-
containing GABAA receptors (zolpidem) (91). The  subunit of the GABAA receptor plays a 
primary role in mediating the sedative pharmacological effects of diazepam and zolpidem 
(92). Hence, their altered pharmacological response could result by a decrease in  subunit-
containing GABAA receptors. Likewise, a decreased  subunits support the formation of 
GABAA receptors in which this subunit might be substituted. Given that subunits are a 
necessary prerequisite for the formation of benzodiazepine-sensitive GABAA receptors (89; 90), 
the lack of anxiolytic activity of diazepam may result from the formation of benzodiazepine-
insensitive GABAA receptors in neuronal circuits that regulate anxiety (39; 91). 
Increases of 4 subunit-containing GABAA receptor expression in the frontal cortex appeared 
to be irrelevant to the behavioral or pharmacological alterations observed in socially isolated 
mice. GABA agonists such as THIP or the allosteric modulator, allopregnanolone, show 
selectivity and increased potency, respectively, for GABAA receptors containing 4/-
subunits. These compounds comparably decrease locomotor activity in group-housed and 
socially isolated mice (91). In contrast to diazepam, allopregnanolone dose-dependently 
induces potent anxiolytic actions in socially isolated mice (16; 39). 
Interestingly, the expression of GABAA receptor subunits is susceptible to changes in brain 
neurosteroid levels. In particular, expression of containing subunits increases during 
progesterone withdrawal or following blockade of reductase (93). Likewise, in socially 
isolated mice, allopregnanolone levels decrease in several corticolimbic structures that 
concomitantly show changes in GABAA receptor subunit mRNA and protein expression. It 
would be important to determine whether social isolation directly affects the expression of 
GABAA receptor subunit composition or whether such changes are mediated by decreasing 
the levels of DHP and its binding at nuclear progesterone receptors or by 
allopregnanolone biosynthesis downregulation.   
8. Selective brain steroidogenic stimulants (SBSSs) improve behavioral 
deficits in socially isolated mice 
Behavioral deficits induced by social isolation in rodents include aggressive behavior (94-
96). Aggression is correlated with the downregulation of corticolimbic allopregnanolone 
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biosynthesis (35). Upregulation of allopregnanolone levels in socially isolated mice by 
systemic administration or local microinfusion of allopregnanolone induces a dose-
dependent amelioration of aggressive behavior of a resident mouse to a same-sex intruder 
(35; 77). Thus, the decrease of corticolimbic allopregnanolone levels appears to be involved 
in the expression of aggression. 
As indicated above, SSRI antidepressants potently increase the levels of allopregnanolone in 
rodents and depressed humans. The effects of paroxetine and fluoxetine on 
allopregnanolone levels were independent from pregnenolone or progesterone levels that 
failed to change (34; 76). Racemic fluoxetine (R- and S-isomers) normalized the righting 
reflex loss induced by pentobarbital in mice by increasing corticolimbic allopregnanolone 
levels (35-37). Of note, at the doses used, fluoxetine failed to change the behavior and 
allopregnanolone levels of group housed mice (35; 36). Importantly, inhibition of serotonin 
synthesis by treatment with p-chlorophenylalanine failed to block the behavioral effects of 
fluoxetine, suggesting that increasing corticolimbic allopregnanolone levels is part of the 
pharmacological actions of fluoxetine (76). 
These observations led us to hypothesize that fluoxetine could improve the behavioral 
abnormalities of socially isolated mice by enhancing corticolimbic allopregnanolone 
biosynthesis rather than by inhibiting serotonin reuptake. This hypothesis was investigated 
using the R- and S-stereoisomers of fluoxetine and norfluoxetine as pharmacological tools. 
We expected that these drugs would stereospecifically upregulate corticolimbic 
allopregnanolone content but have no stereoselectivity with regard to inhibition of 5-HT 
reuptake. We additionally thought that doses of fluoxetine and norfluoxetine stereoisomers 
that increase corticolimbic allopregnanolone content might differ from those that inhibit 5-
HT reuptake. Indeed (16; 35-38), fluoxetine dose-dependently and stereospecifically 
normalized the duration of pentobarbital-induced sedation and reduced aggressiveness, 
fear responses, and anxiety-like behavior at the same submicromolar doses that normalized 
the downregulation of brain allopregnanolone content in socially isolated mice. 
Interestingly, the S-stereoisomers of fluoxetine or norfluoxetine appeared to be 3 to 7 fold 
more potent than their respective R-stereoisomers and S-norfluoxetine was about 5-fold 
more potent than S-fluoxetine. Importantly, the effective concentrations (EC50s) of S-
fluoxetine and S-norfluoxetine that normalize the brain allopregnanolone content are 10- (S-
fluoxetine) and 50-fold (S-norfluoxetine) lower than their respective EC50s needed to inhibit 
5-HT reuptake (35-38). Remarkably, the SSRI activity of S or R-fluoxetine and of S or R-
norfluoxetine was devoid of stereospecificity (35; 36). Hence, this study demonstrated that 
neither the behavioral action nor the normalization of corticolimbic allopregnanolone 
content by S-fluoxetine and S-norfluoxetine is related to their intrinsic SSRI activity.  
9. A novel promising therapy for anxiety disorders and PTSD 
In the pathophysiology of depression and PTSD, a GABAergic neurotransmission 
dysfunction could at least in part be involved in the symptomatology of these disorders. 
Decreased GABA levels and reductions in GABAA and GABAB receptor binding and/or 
sensitivity have been found in depressed patients (97; 98). In PTSD, decreased frontal lobe 
benzodiazepine receptor binding (99; 100) and decreased plasma GABA levels (101) have 
been demonstrated. These changes were most consistently and profoundly observed among 
treatment resistant patients. Benzodiazepines have not been found to effectively treat PTSD 
(10-12) and SSRIs sertraline and paroxetine are the only medications currently approved by 
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the Federal Drug Administration (FDA) for the treatment of PTSD. However, their effect 
sizes are modest (102-105), or even ineffective (106). In patients who cannot adequately 
synthesize allopregnanolone and in whom administration of an SSRI (or SBSS) is ineffective, 
the administration of an allopregnanolone analog (e.g. 107, 108), such as ganaxolone may 
offer a therapeutic alternative. A multisite Phase II trial of the efficacy and safety of 
ganaxolone in PTSD is currently been tested. Other medications that increase plasma 
allopregnanolone levels by a different mechanisms than the SSRIs also may be effective in 
PTSD (109-111).  
The findings that the socially isolated mouse expresses decreased levels of 
allopregnanolone, as well as changes in the expression of several GABAA receptor subunits 
in corticolimbic structures that regulate cognition, anxiety, PTSD, and depression suggests 
that the socially isolated mouse model may be useful in investigating new molecules designed 
to improve behavioral deficits characterized by GABAA receptor signal transduction 
dysfunction (reviewed in 16; 38; 73).  
Hence, as in PTSD patients, the socially isolated mouse fails to respond to sedative and 
anxiolytic benzodiazepines. Our studies demonstrate that allopregnanolone or S-
norfluoxetine -at nonserotonergic doses- infused into the basolateral amygdala potently 
increase allopregnanolone biosynthesis in target corticolimbic areas including the 
hippocampus, basolateral amygdala, and frontal cortex (77) and exert a strong anti-anxiety, 
anti-fear, and anti-aggression effect (35-38; 72; 77).  
Neurosteroids lack GABAA receptor subunit selectivity and the functional GABAA receptor 
binding characteristics of benzodiazepines. Thus, this suggests that allopregnanolone, its 
analogs, or molecules that stimulate allopregnanolone biosynthesis might be advantageous 
over benzodiazepines in a scenario of neurosteroid downregulation and changes in GABAA 
receptor subunit subtypes. Despite benzodiazepines, allopregnanolone activates GABAA 
receptors incorporating ┙4, ┙6, and ├ subunits in combination with ┛ and ┚ subunits (64-66). 
Thus, allopregnanolone or SBSSs improve anxiety, fear, and aggressiveness when 
benzodiazepines fail. Of note and in contrast to benzodiazepines, both allopregnanolone 
and SBSS molecules decrease anxiety, fear, and aggression at concentrations that fail to be 
sedative (16; 35; 39; 77).   
New SBSS molecules that fail to exert any significant SSRI activity but increase corticolimbic 
allopregnanolone levels and thereby improve behavioral symptoms in mouse models of 
anxiety and depression. The high potency and stereospecificity of these drugs in reducing 
behavioral deficits and in normalizing brain allopregnanolone content suggest that they 
may affect specific targets for regulating neurosteroidogenesis. The finding that protracted 
social isolation affects the expression of 5-reductase in corticolimbic structures, but fails to 
change the expression of 3-HSD, as well as the finding that brain progesterone levels don’t 
change in socially isolated mice suggest that a mechanism involving 5-reductase is 
responsible for the decrease of corticolimbic allopregnanolone content. This is further 
supported by the fact that 5-reductase is the rate-limiting step-enzyme in allopregnanolone 
biosynthesis from progesterone (73). Hence, these data suggest that fluoxetine and 
norfluoxetine mediate upregulation of corticolimbic allopregnanolone levels by a direct 
action on 5-reductase. However, in vitro studies by Griffin and Mellon (112) showed that 
fluoxetine, paroxetine, and sertraline failed to activate 5-reductase and instead, directly 
activated 3-HSD by decreasing its Km for 5-DHP, thereby facilitating an accumulation of 
allopregnanolone (112). The hypothesis that neurosteroidogenic antidepressants activate 3-
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HSD is also suggested by the finding that fluoxetine accelerates the rate of allopregnanolone 
accumulation during incubation of brain slices with 5-DHP (34). Furthermore, 
progesterone levels in group-housed and socially isolated mice are not affected by 
fluoxetine administration, suggesting that the SSRI/SBSSs impact neurosteroidogenesis 
downstream from progesterone (34; 76). On the other hand, experiments by Trauger and 
collaborators (113) were inconsistent with the hypothesis that fluoxetine and paroxetine 
directly activate 3-HSD. The finding that low doses of the S isomers of fluoxetine or 
norfluoxetine increase corticolimbic levels of allopregnanolone in socially isolated mice, but 
fail to change levels in group-housed mice, suggests that 5-reductase and/or 3-HSD may 
become more susceptible to the effects of SBSSs during isolation (reviewed in 38). 
Investigations at the molecular enzymatic level will clarify whether social isolation and 
neurosteroidogenic agents change the kinetics of 5-reductase and/or 3-HSD.  
Other feasible pharmacological targets to enhance neurosteroidogenesis include the 
translocase protein (18 kDa) or TSPO, previously called mitochondrial peripheral 
benzodiazepine receptor or PBR (114). TSPO represents the starting point and an important 
rate-limiting step in neurosteroidogenesis.  It gives access to neurosteroids in the brain by 
regulating the entry of cholesterol into the inner mitochondrial membranes and its conversion 
to pregnenolone by P450scc, which is located in the inner mitochondrial membrane (29; 114). 
A cascade of enzymatic processes then take place in the cytosol, resulting in the production of 
neuroactive steroids, including pregnenolone sulfate, DHEAS (though apparently not in 
human brain (115)], THDOC, and allopregnanolone (reviewed in 31).  
New molecules that bind with high affinity to TSPO have been recently investigated. These 
drugs are able to exert important anxiolytic effects but are devoid of the unwanted side 
effects associated with benzodiazepines, including over-sedation and tolerance (28; 29). In 
mouse models, TSPO agents have been shown to potently increase pregnenolone levels in 
the hippocampus and cortex, as well as to induce anxiolytic effects (116-119). TSPO ligands 
include XBD173 and etifoxine, which have proven to be highly efficacious anxiolytic and 
antidepressant drugs in a number of behavioral tests (29; 30). The anxiolytic and 
antidepressant effects of these agents were related their ability to increase neurosteroid 
biosynthesis, as confirmed by studies in which key enzyme blockers for neurosteroid 
biosynthesis, including finansteride and trilostane (56; 30), were used. TSPO ligands have 
recently showed promising therapeutic effects in clinical studies (29; 30).  
10. Closing remarks 
The new class of drugs, the SBSSs (selective brain steroidogenic stimulants) -whose 
mechanism of action involves the stimulation of neurosteroidogenesis with the goal of 
increasing brain allopregnanolone levels- has emerged as a new therapeutic strategy for the 
treatment of psychiatric disorders associated with a downregulation of brain 
allopregnanolone biosynthesis. These disorders include anxiety, depression, and PTSD.  
In comparison to benzodiazepines, the SBSSs are more efficacious as well as devoid of the 
unwanted side-effects induced by benzodiazepines. Allopregnanolone pharmacology 
involves the allosteric modulation of GABA action at GABAA receptors, which is broader 
than that of benzodiazepines, which fail to modulate GABAA receptors containing 4 and 
6 subunits. Hence, selective stimulation of allopregnanolone biosynthesis may avoid the 
therapeutic hindrances caused by the formation of benzodiazepine-resistant GABAA 
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receptors with altered subunit composition, such as may occur in stress-related psychiatric 
disorders (reviewed in 120). Thus, novel SBSS drugs that specifically increase corticolimbic 
allopregnanolone biosynthesis appear to be a novel promising pharmacological class of 
future drugs for the treatment of anxiety disorders, depression, and PTSD. 
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